AIM Vaccine Co., Ltd. (HKG:6660)
Hong Kong · Delayed Price · Currency is HKD 3.100
+0.030 (0.98%)
Feb 13, 2026, 3:31 PM HKT
AIM Vaccine Revenue
AIM Vaccine had revenue of 514.66M CNY in the half year ending June 30, 2025, a decrease of -4.78%. This brings the company's revenue in the last twelve months to 1.26B, up 6.62% year-over-year. In the year 2024, AIM Vaccine had annual revenue of 1.29B with 8.22% growth.
Revenue (ttm)
1.26B CNY
Revenue Growth
+6.62%
P/S Ratio
2.72
Revenue / Employee
845.62K CNY
Employees
1,493
Market Cap
3.77B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.29B | 97.56M | 8.22% |
| Dec 31, 2023 | 1.19B | -76.61M | -6.06% |
| Dec 31, 2022 | 1.26B | -306.06M | -19.49% |
| Dec 31, 2021 | 1.57B | -67.84M | -4.14% |
| Dec 31, 2020 | 1.64B | 686.32M | 72.12% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Viva Biotech Holdings | 2.01B |
| BioDlink International Company | 1.17B |
| Shandong Boan Biotechnology | 829.27M |
| Medtide | 546.29M |
| Qyuns Therapeutics | 351.04M |
| Jacobio Pharmaceuticals Group | 220.66M |
| Clover Biopharmaceuticals | 56.73M |
| Jiangsu Recbio Technology | 31.90M |